Přejít k obsahu
Merck

A review of flavoxate hydrochloride in the treatment of urge incontinence.

The Journal of international medical research (1988-09-01)
R Ruffmann
ANOTACE

This article provides a review of the use of flavoxate hydrochloride in the treatment of urge incontinence. It outlines the pharmacology, mode of action, toxicology and pharmacokinetic studies which have been carried out, and then reviews the clinical studies, including those involving patients with benign prostatic hypertrophy. The effects of dosages of 600-1200 mg/day are compared, particularly regarding safety and tolerability factors. Finally, alternative therapies to flavoxate hydrochloride (alpha-adrenergic receptor blockers, oxybutinin chloride, terodiline hydrochloride, emepronium bromide and imipramine) are summarized. The article is written in the knowledge of recent evidence which indicates that flavoxate hydrochloride exhibits only weak anticholinergic activity on receptors involved in the control of the lower urinary tract.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Flavoxate hydrochloride, European Pharmacopoeia (EP) Reference Standard
USP
Flavoxate hydrochloride, United States Pharmacopeia (USP) Reference Standard